Hereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries

At a consensus meeting in August 2018, pediatricians and dermatologists from German‐speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE‐C1‐INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE‐C1‐INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life‐threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This article provides recommendations for developing appropriate treatment strategies in the management of HAE‐C1‐INH in pediatric patients in German‐speaking countries. An overview of available drugs in this age‐group is provided, together with their approval status, and study results obtained in adults and pediatric patients.

[1]  E. Mansour,et al.  Hereditary angioedema in children and adolescents. , 2022, Allergologia et immunopathologia.

[2]  William H. Yang,et al.  Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. , 2019, The journal of allergy and clinical immunology. In practice.

[3]  T. Machnig,et al.  Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. , 2019, The journal of allergy and clinical immunology. In practice.

[4]  I. Braenne,et al.  Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N‐terminal cleavage site of bradykinin , 2019, Allergy.

[5]  Ting Qiu,et al.  Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema , 2019, Allergy.

[6]  H. Farkas,et al.  Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[7]  Moshe Y. Vardi,et al.  A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema , 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[8]  A. Maetzel,et al.  KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On‐Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study: 116 , 2019, Journal of Allergy and Clinical Immunology.

[9]  W. Aberer,et al.  Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On‐Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH‐1 Trial: 110 , 2019, Journal of Allergy and Clinical Immunology.

[10]  T. Biedermann,et al.  Guideline: Hereditary angioedema due to C1 inhibitor deficiency , 2019, Allergo Journal International.

[11]  William H. Yang,et al.  Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.

[12]  J. Dempster.  Practicalities of a reduced volume formulation of a C1-INH concentrate for the treatment of hereditary angioedema: real-life experience , 2018, Allergy, Asthma & Clinical Immunology.

[13]  Michael J. Wilson,et al.  Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. , 2018, The Journal of allergy and clinical immunology.

[14]  L. Gesualdo,et al.  A transcriptomics study of hereditary angioedema attacks , 2018, The Journal of allergy and clinical immunology.

[15]  M. Triggiani,et al.  Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema , 2018, The New England journal of medicine.

[16]  A. Franzese,et al.  Emotional processes and stress in children affected by hereditary angioedema with C1-inhibitor deficiency: a multicenter, prospective study , 2018, Orphanet Journal of Rare Diseases.

[17]  M. Cicardi,et al.  Angioedema Due to Bradykinin Dysregulation. , 2018, The journal of allergy and clinical immunology. In practice.

[18]  P. Schmid‐Grendelmeier,et al.  Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema , 2018, Orphanet Journal of Rare Diseases.

[19]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[20]  W. Aberer,et al.  Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. , 2017, The journal of allergy and clinical immunology. In practice.

[21]  C. Koch,et al.  Complement factor C4 activation in patients with hereditary angioedema. , 2017, Clinical biochemistry.

[22]  H. Longhurst,et al.  Prophylactic Therapy for Hereditary Angioedema. , 2017, Immunology and allergy clinics of North America.

[23]  C. Maas,et al.  Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment. , 2017, Immunology and allergy clinics of North America.

[24]  J. Bernstein,et al.  Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. , 2017, The journal of allergy and clinical immunology. In practice.

[25]  William H. Yang,et al.  Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.

[26]  M. Triggiani,et al.  International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency , 2016, Allergy.

[27]  J. Bernstein,et al.  Short-term prophylactic use of C1-inhibitor concentrate in hereditary angioedema: Findings from an international patient registry. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[28]  J. McCall,et al.  Hereditary Angioedema as a Metabolic Liver Disorder: Novel Therapeutic Options and Prospects for Cure , 2016, Front. Immunol..

[29]  C. Escuriola Ettingshausen,et al.  Delayed diagnosis of hereditary angioedema: Thirty-nine years of inadequate treatment. , 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[30]  J. Bernstein,et al.  Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency , 2016, Pediatrics.

[31]  H. Farkas,et al.  Erythema Marginatum as an Early Symptom of Hereditary Angioedema: Case Report of 2 Newborns , 2016, Pediatrics.

[32]  W. Aberer,et al.  Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema. , 2016, Journal of investigational allergology & clinical immunology.

[33]  W. Lumry,et al.  Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3 , 2015, International Archives of Allergy and Immunology.

[34]  W. Lumry,et al.  Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[35]  W. Aberer,et al.  Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey. , 2015, Allergy and asthma proceedings.

[36]  Michael J. Wilson,et al.  Development and Characterization of an Anti-FXIIa Monoclonal Antibody for the Treatment of Hereditary Angioedema , 2015 .

[37]  G. V. Marcotte,et al.  Hereditary angioedema: imaging manifestations and clinical management , 2015, Emergency Radiology.

[38]  W. Lumry,et al.  Repeat treatment of acute hereditary angioedema attacks with open‐label icatibant in the FAST‐1 trial , 2014, Clinical and experimental immunology.

[39]  W. Kreuz,et al.  Characterization of prodromal symptoms in a large population of patients with hereditary angio‐oedema , 2014, Clinical and experimental dermatology.

[40]  Y. Tomino,et al.  Clinical and laboratory characteristics that differentiate hereditary angioedema in 72 patients with angioedema. , 2014, Allergology international : official journal of the Japanese Society of Allergology.

[41]  P. Schmid‐Grendelmeier,et al.  Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST‐2 open‐label study , 2013, Allergy.

[42]  J. Scolapio,et al.  Gastrointestinal Manifestations, Diagnosis, and Management of Hereditary Angioedema , 2013, Journal of clinical gastroenterology.

[43]  M. Maurer,et al.  Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe , 2013, Allergy, Asthma & Clinical Immunology.

[44]  B. Monia,et al.  Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. , 2013, Nucleic acid therapeutics.

[45]  W. Lumry,et al.  Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. , 2013, The Journal of pediatrics.

[46]  W. Aberer,et al.  Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment , 2013, PloS one.

[47]  T. Machnig,et al.  C1‐INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies , 2013, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[48]  B. Zuraw,et al.  Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. , 2012, The American journal of medicine.

[49]  D. Meyer‐Olson,et al.  Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies , 2012, European Journal of Pediatrics.

[50]  T. Klingebiel,et al.  Home therapy with intravenous human C1‐inhibitor in children and adolescents with hereditary angioedema , 2012, Transfusion.

[51]  P. Busse,et al.  Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[52]  T. Machnig,et al.  C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks – final results of the I.M.P.A.C.T.2 study , 2011, Allergy.

[53]  C. Town,et al.  Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[54]  K. Bork,et al.  Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[55]  M. Cicardi,et al.  Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21‐month prospective study in a cohort of 103 patients , 2011, Allergy.

[56]  J. Nuijens,et al.  Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.

[57]  J. Bernstein,et al.  Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. , 2010, The New England journal of medicine.

[58]  William H. Yang,et al.  Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.

[59]  J. Bernstein,et al.  Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.

[60]  H. Griffiths,et al.  Normal complement C4 values do not exclude hereditary angioedema , 2004, Journal of Clinical Pathology.

[61]  K. Bork,et al.  Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. , 2003, The American journal of medicine.

[62]  H. Farkas,et al.  Danazol therapy for hereditary angio-oedema in children , 1999, The Lancet.

[63]  A. Sheffer,et al.  Tranexamic acid therapy in hereditary angioneurotic edema. , 1972, The New England journal of medicine.

[64]  D. Alling,et al.  Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. , 1972, The New England journal of medicine.